Black Diamond Therapeutics (BDTX) Income towards Parent Company (2018 - 2026)

Black Diamond Therapeutics (BDTX) has 9 years of Income towards Parent Company data on file, last reported at -$11.4 million in Q1 2026.

• Quarterly Income towards Parent Company fell 121.06% year-over-year to -$11.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$57.2 million (down 43.98% YoY) and the FY2025 annual result came in at -$107.6 million, up 47.28% from the prior year.
• Income towards Parent Company climbed to -$11.4 million in Q1 2026, from -$17.6 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $54.0 million in Q1 2025 to a low of -$57.3 million in Q3 2022.
• A 5-year average of -$22.5 million and a median of -$22.0 million in 2023 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2025 — Income towards Parent Company soared 361.09% — and 2026, when it tumbled 121.06%.
• Tracing BDTX's Income towards Parent Company over 5 years: stood at -$22.2 million in 2022, then gained by 2.77% to -$21.6 million in 2023, then increased by 12.92% to -$18.8 million in 2024, then increased by 6.66% to -$17.6 million in 2025, then jumped by 35.24% to -$11.4 million in 2026.
• The last three Income towards Parent Company figures came in at -$11.4 million (Q1 2026), -$17.6 million (Q4 2025), and -$15.3 million (Q3 2025), per Business Quant data.